Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.

Related Articles Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. Cancer Treat Rev. 2020 Sep;89:102069 Authors: Uijen MJM, Lassche G, van Engen-van Grunsven ACH, Tada Y, Verhaegh GW, Schalken JA, Driessen CML, van Herpen CML Abstract BACKGROUND: Salivary duct carcinoma (SDC) is an aggressive subtype of salivary gland cancer. Approximately half of SDC patients will develop recurrences or metastases. Therapeutic palliative therapy is therefore often needed. The majority of SDC tumors expresses the androgen receptor (AR) and one-third expresses human epidermal growth factor receptor 2 (HER2), both are potential therapeutic targets. The aim…
Origen: Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. – PubMed